Xencor, Inc. (XNCR) Major Shareholder John S. Stafford III Acquires 6,000 Shares
Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III acquired 6,000 shares of the business’s stock in a transaction dated Wednesday, June 28th. The stock was purchased at an average price of $19.94 per share, for a total transaction of $119,640.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Xencor, Inc. (XNCR) traded down 0.33% during midday trading on Friday, hitting $21.11. The company had a trading volume of 259,847 shares. Xencor, Inc. has a one year low of $17.65 and a one year high of $29.38. The firm has a market cap of $985.90 million, a price-to-earnings ratio of 59.80 and a beta of 2.13. The company’s 50 day moving average is $21.44 and its 200 day moving average is $23.56.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.06. Xencor had a return on equity of 5.98% and a net margin of 18.19%. The company had revenue of $4.34 million during the quarter, compared to analyst estimates of $8.15 million. Equities analysts forecast that Xencor, Inc. will post ($1.21) earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of XNCR. Two Sigma Investments LP boosted its position in Xencor by 50.3% in the fourth quarter. Two Sigma Investments LP now owns 49,404 shares of the biopharmaceutical company’s stock valued at $1,300,000 after buying an additional 16,523 shares in the last quarter. Norges Bank acquired a new position in Xencor during the fourth quarter valued at $15,601,000. Metropolitan Life Insurance Co. NY boosted its position in Xencor by 5.2% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 24,914 shares of the biopharmaceutical company’s stock valued at $656,000 after buying an additional 1,227 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Xencor during the fourth quarter valued at $2,213,000. Finally, Creative Planning boosted its position in Xencor by 2.7% in the first quarter. Creative Planning now owns 38,400 shares of the biopharmaceutical company’s stock valued at $919,000 after buying an additional 1,000 shares in the last quarter. 75.00% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have recently commented on XNCR shares. Zacks Investment Research downgraded Xencor from a “buy” rating to a “hold” rating in a report on Saturday, April 29th. Wedbush restated an “outperform” rating and issued a $29.00 price objective on shares of Xencor in a report on Wednesday, May 10th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $28.67.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.